Last reviewed · How we verify
KPI-121 Ophthalmic Suspension
KPI-121 Ophthalmic Suspension is a TRPV1 antagonist / Topical anti-inflammatory Small molecule drug developed by Kala Pharmaceuticals, Inc.. It is currently in Phase 3 development for Dry eye disease (keratoconjunctivitis sicca), Ocular surface inflammation.
KPI-121 is a topical ophthalmic suspension that reduces ocular inflammation and promotes corneal healing through inhibition of transient receptor potential vanilloid 1 (TRPV1) and modulation of inflammatory pathways.
KPI-121 is a topical ophthalmic suspension that reduces ocular inflammation and promotes corneal healing through inhibition of transient receptor potential vanilloid 1 (TRPV1) and modulation of inflammatory pathways. Used for Dry eye disease (keratoconjunctivitis sicca), Ocular surface inflammation.
At a glance
| Generic name | KPI-121 Ophthalmic Suspension |
|---|---|
| Sponsor | Kala Pharmaceuticals, Inc. |
| Drug class | TRPV1 antagonist / Topical anti-inflammatory |
| Target | TRPV1 (Transient Receptor Potential Vanilloid 1) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
KPI-121 is formulated as a mucoadhesive suspension designed to deliver anti-inflammatory and neuroprotective effects to the ocular surface. The drug targets inflammatory mediators and nerve fiber dysfunction associated with dry eye disease and other ocular surface conditions, with enhanced corneal penetration and residence time due to its proprietary formulation technology.
Approved indications
- Dry eye disease (keratoconjunctivitis sicca)
- Ocular surface inflammation
Common side effects
- Instillation site discomfort
- Conjunctival hyperemia
- Eye irritation
Key clinical trials
- Safety and Efficacy of KPI-121 in Subjects With DED (PHASE3)
- Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease (PHASE3)
- Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation (PHASE3)
- Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease (PHASE2)
- Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease (PHASE2)
- Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease (PHASE3)
- Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain (PHASE3)
- Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KPI-121 Ophthalmic Suspension CI brief — competitive landscape report
- KPI-121 Ophthalmic Suspension updates RSS · CI watch RSS
- Kala Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about KPI-121 Ophthalmic Suspension
What is KPI-121 Ophthalmic Suspension?
How does KPI-121 Ophthalmic Suspension work?
What is KPI-121 Ophthalmic Suspension used for?
Who makes KPI-121 Ophthalmic Suspension?
What drug class is KPI-121 Ophthalmic Suspension in?
What development phase is KPI-121 Ophthalmic Suspension in?
What are the side effects of KPI-121 Ophthalmic Suspension?
What does KPI-121 Ophthalmic Suspension target?
Related
- Drug class: All TRPV1 antagonist / Topical anti-inflammatory drugs
- Target: All drugs targeting TRPV1 (Transient Receptor Potential Vanilloid 1)
- Manufacturer: Kala Pharmaceuticals, Inc. — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Dry eye disease (keratoconjunctivitis sicca)
- Indication: Drugs for Ocular surface inflammation
- Compare: KPI-121 Ophthalmic Suspension vs similar drugs
- Pricing: KPI-121 Ophthalmic Suspension cost, discount & access